Therapeutics News and Research

RSS

Florida Hospital, Sanford-Burnham and Takeda renew research agreement

Sanford-Burnham Medical Research Institute (Sanford-Burnham) and Florida Hospital announced today that they have renewed a research agreement with Takeda Pharmaceutical Company Limited (Takeda) to extend their collaboration to discover and evaluate new therapeutic approaches to obesity. The collaboration uses a research and drug-development model that creates an early feedback loop in the discovery pipeline.

12 Feb 2013

RNF20 protein required for MLL-rearranged leukemia amplification

Acute myeloid leukemia (AML) is an aggressive blood cancer that is currently incurable in 70% of patients. In a bold effort, CSHL scientists are among those identifying and characterizing the molecular mechanisms responsible for this cancer in order to generate potential new therapeutics.

12 Feb 2013

Unilife revenues decrease to $0.7 million for three months ended December 31, 2012

Unilife Corporation, a developer and supplier of injectable drug delivery systems, today announced its financial results for the quarter ended December 31, 2012, (the second quarter of Fiscal Year 2013).

12 Feb 2013

Sunitinib shows promise against metastatic renal cell carcinoma

Findings from clinical trial patients with metastatic renal cell carcinoma, a common kidney cancer, show they did not have accelerated tumor growth after treatment with sunitinib, in contrast to some study results in animals. Sunitinib is one of several drugs, either on the market or undergoing testing, that target blood vessel growth.

10 Feb 2013

Novel combination of ibrutinib and bortezomib could be effective new therapy for blood cancers

Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective new therapy for several forms of blood cancer, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).

7 Feb 2013

Studies to identify molecular causes and preventive and therapeutic strategies for Parkinson's

On the fourth floor of Wichita State University's McKinley Hall, biochemistry professor Kandatege Wimalasena and his group of doctoral and undergraduate students are hard at work researching Parkinson's disease (PD) - the second-most common neurodegenerative disease, affecting 1 to 2 percent of people older than 60.

7 Feb 2013

Sangamo BioSciences fourth quarter revenues increase to $8.9 million

Sangamo BioSciences, Inc. today reported fourth quarter and full year 2012 financial results and accomplishments.

7 Feb 2013

RRM1 gene may better predict survival for pancreatic adenocarcinoma

Moffitt Cancer Center researchers have identified a gene that may better predict survival for pancreatic adenocarcinoma, the fourth leading cause of cancer deaths in the United States.

6 Feb 2013

Acceleron commences dalantercept phase 2 study in metastatic renal cell carcinoma

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, announced the initiation of a phase 2 study of dalantercept, a novel angiogenesis inhibitor that targets the activin receptor-like kinase 1 (ALK1) pathway.

5 Feb 2013

Acceleron Pharma initiates dalantercept phase 2 study in advanced ovarian cancer

Acceleron Pharma, a biopharmaceutical company developing protein therapeutics for cancer and orphan disease, today announced that the Gynecologic Oncology Group (GOG) initiated a phase 2 study of dalantercept in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer.

5 Feb 2013

BrainStorm initiates NurOwn Phase IIa dose-escalating trial in ALS

BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the first patient began treatment in the Company's Phase IIa dose-escalating clinical trial for ALS.

5 Feb 2013

Study provides new insight on cancer prevention

Clear communication between cells is essential to every aspect of the body's internal function. But since cells can't talk, or send emails, how do they communicate?

4 Feb 2013

Study shows how placental circulation can influence malarial parasite behavior and infection

Malaria in pregnancy causes a range of adverse effects, including abortions, stillbirths, premature delivery and low infant birth weight. Many of these effects are thought to derive from a placental inflammatory response resulting from interaction of infected red blood cells with the placental tissue.

3 Feb 2013

Two new methods could accelerate development of improved antisense drugs

Powerful antisense drugs that target disease-associated genes to block their expression can be used to treat a broad range of diseases. Though antisense therapy has been proven effective, challenges remain in ensuring that the drugs reach their intended targets.

2 Feb 2013

Study shows how female steroid hormones can make changes to the breast genetic material

Melbourne scientists have discovered how female steroid hormones can make dramatic changes to the genetic material in breast cells, changes that could potentially lead to breast cancer.

2 Feb 2013

Hyperion Therapeutics receives FDA approval for Ravicti to treat urea cycle disorders

The U.S. Food and Drug Administration today approved Ravicti (glycerol phenylbutyrate) for the chronic management of some urea cycle disorders (UCDs) in patients ages 2 years and older.

1 Feb 2013

Scientists identify specific p53 pocket that can be targeted by cancer-fighting drugs

UC Irvine biologists, chemists and computer scientists have identified an elusive pocket on the surface of the p53 protein that can be targeted by cancer-fighting drugs. The finding heralds a new treatment approach, as mutant forms of this protein are implicated in nearly 40 percent of diagnosed cases of cancer, which kills more than half a million Americans each year.

1 Feb 2013

Galectin submits GR-MD-02 IND application with FDA for treatment of liver fibrosis

Galectin Therapeutics, the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that it submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on January 30, 2013.

1 Feb 2013

Gene variant boosts ulcer susceptibility in NSAID users

A single nucleotide polymorphism in the cytochrome P450 2C gene cluster influences the risk for peptic ulcer disease in people taking non-steroidal anti-inflammatory drugs, a study reveals.

31 Jan 2013

Finding medical applications for unused inventions: an interview with Gabriel Mecklenburg, Co-Founder of Marblar

Marblar is gamifying the process of technology transfer. We post technology on our platform in the form of a challenge, and the Marblar community then competes to uncover new problems these technologies could solve – thereby discovering new market applications for these technologies.

31 Jan 2013

Therapeutics News and Research

Florida Hospital, Sanford-Burnham and Takeda renew research agreement

RNF20 protein required for MLL-rearranged leukemia amplification

Unilife revenues decrease to $0.7 million for three months ended December 31, 2012

Sunitinib shows promise against metastatic renal cell carcinoma

Novel combination of ibrutinib and bortezomib could be effective new therapy for blood cancers

Studies to identify molecular causes and preventive and therapeutic strategies for Parkinson's

Sangamo BioSciences fourth quarter revenues increase to $8.9 million

RRM1 gene may better predict survival for pancreatic adenocarcinoma

Acceleron commences dalantercept phase 2 study in metastatic renal cell carcinoma

Acceleron Pharma initiates dalantercept phase 2 study in advanced ovarian cancer

BrainStorm initiates NurOwn Phase IIa dose-escalating trial in ALS

Study provides new insight on cancer prevention

Study shows how placental circulation can influence malarial parasite behavior and infection

Two new methods could accelerate development of improved antisense drugs

Study shows how female steroid hormones can make changes to the breast genetic material

Hyperion Therapeutics receives FDA approval for Ravicti to treat urea cycle disorders

Scientists identify specific p53 pocket that can be targeted by cancer-fighting drugs

Galectin submits GR-MD-02 IND application with FDA for treatment of liver fibrosis

Gene variant boosts ulcer susceptibility in NSAID users

Finding medical applications for unused inventions: an interview with Gabriel Mecklenburg, Co-Founder of Marblar

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News